News

EC approves BeOne’s Tevimbra for nasopharyngeal carcinoma
BeOne Medicines has secured approval from the European Commission (EC) for Tevimbra (tislelizumab) to be used along with ...
Scientists develop novel recording tool to monitor protein kinase activities in living cells
The ability of protein kinases to transfer a phosphate group to target proteins plays an important role in many cellular ...
Agence France-Presse2d
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA ® (tislelizumab), in combination with gemcitabine and cisplatin, ...
Mid-Day3d
Here's why cancer treatments may trigger serious side-effects, according to a study
The findings clarify that side effects of cancer treatments may be linked to a specific protein’s critical role in cellular ...
Hidden role of 'cell protector' protein opens cancer treatment possibilities
Recent research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some ...
News-Medical.Net4d
Landmark discovery reshapes understanding of key cancer protein MCL-1
Landmark research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some promising cancer treatments are causing serious side effects, and offers ...